Hit.Ax

HIT.AX maintains a strong liquidity position, with a current ratio of 2.69 and cash and equivalents amounting to AUD 6.84 million, which represents 38% of total assets. The company's debt-to-equity ratio is 0.04, indicating a conservative capital structure with minimal reliance on long-term debt. Free cash flow of AUD 1.98 million and operating cash flow of AUD 2.68 million further support its liquidity and financial flexibility.

In terms of profitability, HIT.AX reports a return on equity (ROE) of 55.15% and a return on assets (ROA) of 35.49%, both significantly above the typical thresholds for the Employment Services industry. The company's operating income of AUD 8.93 million and net income of AUD 6.38 million reflect strong operational performance and efficient cost management.

HIT.AX operates as a single business segment, with no disclosed geographic diversification in the latest financial data. The company's revenue is concentrated in one primary market, which may expose it to regional economic fluctuations.

Looking ahead, HIT.AX is projected to maintain a stable growth trajectory, with no significant changes in revenue expected in the next fiscal year. The company's historical revenue of AUD 68.15 million provides a baseline for future performance. However, the absence of disclosed capital expenditure plans suggests a focus on maintaining current operations rather than aggressive expansion.

The risk assessment for HIT.AX indicates low liquidity and dilution risks, with no immediate filing-based flags detected. The company's low debt levels and strong cash reserves reduce the likelihood of financial distress. Additionally, the absence of dilution sources in recent filings suggests a stable capital structure.

No recent events, such as filings or transcripts, have been disclosed that would significantly impact HIT.AX's operations or financial position. The company appears to be operating in a stable environment with no major disruptions reported.

Health In Tech Inc (HIT.O) has recorded a notable addition to its shareholder base, marking a significant development for the company. As of March 31, 2026, investor ID 471 acquired a position of 183,325 shares, valued at approximately $0.27 million. This transaction represents a weight of roughly 0.0017% in the investor's portfolio and was detected on June 20, 2026. This activity is particularly relevant as it constitutes the first analysis available for this ticker, meaning there is no prior basis for computing delta changes in shareholder composition. The emergence of this new holder provides the initial data point for tracking institutional or significant investor interest in Health In Tech Inc. The significance of this change lies in the context of the company's current profile. Health In Tech Inc currently reports zero officers, zero analyst coverage, and no index memberships. The entry of a new holder into a company with such limited public market infrastructure may signal early-stage interest or specific strategic positioning by the investor. With only six top holders identified in total, the addition of investor ID 471 contributes to the sparse ownership structure of Health In Tech Inc. This development warrants monitoring to see if it precedes further analyst coverage or corporate governance updates, given the current absence of these standard market indicators.

Analysts project 272.8% upside to a mean price target of $4.25, signaling strong potential for significant share price appreciation.

The company maintains a low leverage band with a debt-to-equity ratio of 0.35, indicating a conservative capital structure.

Operating margin of 6.49% matches the cohort median, demonstrating competitive operational efficiency within the life and health insurance sector.

Revenue reached $33.3 million in FY0, showing substantial scale compared to $5.8 million in FY-3 despite recent volatility.

The firm generated positive net income of $1.28 million in FY0, confirming its ability to achieve profitability in recent periods.

Return on equity of 1.62% sits in the bottom quartile of the cohort, indicating poor capital efficiency relative to peers.

Cash conversion of -6.77 ranks in the bottom quartile, suggesting significant challenges in generating cash from operations.

Net margin of 1.96% falls below the cohort median of 3.84%, reflecting weaker bottom-line performance than industry peers.